Ignite Creation Date:
2025-12-24 @ 7:30 PM
Ignite Modification Date:
2025-12-25 @ 5:11 PM
Study NCT ID:
NCT01356303
Status:
SUSPENDED
Last Update Posted:
2016-05-13
First Post:
2011-03-19
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Docetaxel Combined With Cisplatin as First Line in Patients With Metastatic Non-small Cell Lung Cancer
Sponsor:
National Guard Health Affairs
Organization:
Study Overview
Official Title:
A Phase II Study of Docetaxel Combined With Cisplatin as the First Line Chemotherapy in Patients With Metastatic Non-small Cell Lung Cancer
Status:
SUSPENDED
Status Verified Date:
2016-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Difficulty in enrolling patients
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TAXIS01
Brief Summary:
This is a phase II, open-label clinical study prospectively enrolling 40 metastatic patients with non small cell lung cancer. The study will enroll patients at King Abdulaziz Medical City, Riyadh.
Sub-sites will be open for patient accrual in selected centers in the Kingdom.
Sub-sites will be open for patient accrual in selected centers in the Kingdom.
Detailed Description:
The cisplatin/docetaxel is established standard in the first line management of metastatic non small cell lung cancer in the United States, Europe and Asia. However, the safety and efficacy of this regimen was not studied systematically in Middle Eastern population. The aim of this study is to study the efficacy and safety of this regimen in our patient population
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: